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1. Introduction  
The cellular mechanisms underlying neuronal loss and neurodegeneration have been an 
area of great interest for neuroscientists throughout the world. The development of animal 
models that simulate critical components of clinical neurodegenerative diseases have 
provided tremendous insight into the pathophysiological pathways and have facilitated the 
application of targeted pharmacotherapy. Although neurodegenerative diseases (ND), such 
as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), 
Huntington’s disease (HD), and multiple sclerosis (MS) each have distinct clinical symptoms 
and pathologies, they also share common mechanisms such as intra- and/or extracellular 
accumulation of misfolded proteins; apoptosis; neuroinflammation; mitochondrial injury, 
oxidative stress and excitotoxic insult (Tarawneh and Galvin, 2010). No one mechanism 
appears to be primary in all cases of a particular ND, and these pathogenic most 
mechanisms most likely act synergistically through complex interactions to promote 
neurodegeneration. Discussion of these mechanisms is briefly reviewed here in reference to 
their implications for the development of novel neuroprotective /neuro-restorative agents 
targeting one or more of these pathways. 
2. Misfolding of protein: An important target of treatment for 
neurodegenerative diseases 
Protein misfolding is the physical process by which a polypeptide folds into its characteristic 
and functional three dimensional structures. Failure to fold into native structure results in 
inactive protein which is referred to as misfolded protein (Soto, 2003). Neuronal tissues are 
exquisitely sensitive to defective protein folding, and the accumulation of misfolded proteins 
is proteotoxic due to dominant effects of insolubility, inappropriate intermolecular 
interactions, and long half-lives (Neef et al., 2010). Protein misfolding and improper processing 
by the cellular quality-control system causes many highly debilitating disorders, ranging from 
heritable diseases, such as cystic fibrosis (CF) and 1-antitrypsin deficiency as well as several 
other several neurodegenerative disorders (Soto, 2003; Singh, 2010). Hereditary protein 
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conformational disorders are characterized by coding region trinucleotide expansions 
resulting in the insertion of poly-glutamine (polyQ) tracts that adopt -sheet structures and 
that are prone to incorrect folding and aggregation (Neef et al., 2010; Soto, 2003). Expansion of 
poly Q tracts has been associated with at least nine neurodegenerative diseases (Khare et al., 
2005). There are currently no cure for any of the polyQ diseases, but researchers hypothesize 
that if the abnormal polyQ proteins could be stabilized into their correct conformation, the 
neurotoxicity associated with protein misfolding in neuronal tissues might be prevented, 
leading to arrest of the disease process (Heller, 2010).  
2.1 Alzheimer’s disease (AD) 
Alzheimer’s disease is characterized by the aggregation and accumulation of two proteins: 
amyloid beta-peptide (A) which is deposited in extracellular senile plaques and the 
microtubule-associated protein tau which accumulates in a highly phosphorylated form as 
paired helical filaments that comprise the intraneuronal neurofibrillary tangles (NFTs) and 
neuropil threads (Hanger et al., 2009). In AD, tau appears to become hyperphosphorylated, 
which may contribute to destabilization of microtubules and may be incorporated into 
neuro-fibrillary tangles. One approach used with transgenic mice has involved NAP (Asn-
Ala-Pro- Val-Ser-Ile-Pro-Gln; NAPVSIPQ), an octapeptide that prevents disruption of 
microtubules by binding to tubulin. Administration of this compound decreased 
hyperphosphorylation of tau and improved cognitive function in mice (Matsuoka et al., 
2008), recently this drug has entered a clinical trial (Potter, 2010). Another approach focuses 
on enzymes involved in phosphorylating tau. Glycogen synthase kinase-3 (GSK-3), has been 
shown to cause hyperphosphorylation of tau when over expressed in transgenic mice, and 
inhibition of this enzyme decreases levels of ǃ-amyloid (Phiel et al., 2003). Lithium chloride 
by inhibiting GSK-3, decreases hyperphosphorylation of tau and improves cognition (Noble 
et al., 2005).  
One of the approaches to decrease the levels of ǃ-amyloid is passive immunization with 
antibodies targeting portions of the ǃ-amyloid molecule. Bapineuzumab (AAB-001) is a 
humanized monoclonal antibody to the N-terminus of ǃ -amyloid. Two phase 2 trials have 
been conducted with this drug. In one trial, cortical ǃ-amyloid load was significantly 
decreased (Rinne et al., 2010). In the other trial, no statistically significant difference in 
cognitive function was found (Salloway et al., 2009). Interestingly, bapineuzumab appeared 
to produce some beneficial cognitive effects in individuals who did not have the e4 allelle of 
the apolipoprotein E (ApoE) gene, but those results were not statistically significant (Rinne 
et al., 2010). Treatment with bapineuzumab has also been found to reduce tau levels in 
patients with AD in two clinical trials (Kerchner & Boxer, 2010). A phase 3 clinical trial is 
currently being conducted with bapineuzumab. Ponezumab (PF- 04360365), an antibody 
targeted to the free carboxy terminus of ǃ-amyloid 1-40, has undergone preliminary human 
trials and has been shown to increase CSF ǃ-amyloid (Zhao et al., 2010). It seems likely that 
drugs targeting ǃ-amyloid would need to be given to patients early in the course of 
disease—before neurodegeneration becomes severe enough to impair cognitive function 
(Potter, 2010). 
The most common pathogenesis of familial AD involves misprocessing of amyloid 
precursor protein (APP) by enzyme gamma secretase. Targeting of gamma-secretase is 
another area of drug development for AD (Tomita, 2009). One of these gamma-secretase 
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inhibitors, begacestat (GSI- 953), decreased plasma levels, but not CSF levels, of ǃ-amyloid 
in humans (Jacobsen et al., 2009; Martone et al., 2009). Another gamma-secretase inhibitor, 
BMS- 708163, decreased CSF levels of ǃ-amyloid in humans (Ereshfksy et al., 2009).  
A third gamma- secretase inhibitor, PF-3084014 ([(S)-2-((S)-5,7- difluoro-1,2,3,4-
tetrahydronaphthalen-3-ylamino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-
imidazol-4-yl), pentanamide]), decreased plasma and CSF levels of ǃ-amyloid in animals, 
but only plasma levels in humans (Soares et al., 2009). Stimulation of ά-secretase leads to 
non-amyloidogenic processing of amyloid processing protein (APP). Some of the muscarinic 
agonists have been shown to increase ά-secretase activity, and a number of other drugs are 
being investigated for their ability to inhibit gamma secretase (Mangliasche et al., 2010).  
Inhibition of tau aggregation is yet another approach. Immunotherapy with antibodies 
directed at tau decreased tangles in the Tg P301L mouse model (Asuni et al., 2007). Another 
avenue that has currently passed a phase 2 trial is blocking tau aggregation with methylene 
blue (Staff et al., 2008). Methylene blue has also been shown to enhance mitochondrial 
function (Pandey et al., 2008), and decrease the levels of ǃ-amyloid, and cognitive deficits in 
3xTg-AD transgenic mice (Medina et al., 2011). A larger phase 3 trial has been planned. 
Other such inhibitors which are being studied as potential therapeutic agents for AD 
include phenothiazines, porphyrins and polyphenols (Brunden et al., 2009).  
Heat shock protein 90 (Hsp90) is a member of a large family of molecules that help in 
regulating pathogenic transformation, and the stability of abnormally folded neuronal 
proteins, allowing the accumulation of toxic aggregates (Lu et al., 2009; Luo et al., 2010). 
Inhibition of Hsp 90 activates heat shock factor I (HSF- I) to induce production of Hsp 70 
and Hsp40 as well as other chaperones may be promising treatment for AD and other 
neurodegenerative diseases (Luo et al., 2010). A new Hsp90 inhibitor novobiocin provided 
excellent neuroprotection, with little or no toxicity in a cell culture model of beta-amyloid 
(Lu et al., 2009).  
2.2 Parkinson’s disease (PD) 
PD is characterized mainly by progressive and selective loss of dopaminergic neurons in the 
substantia nigra pars compacta, with subsequent dopamine (DA) decline in the nigrostriatal 
pathway, and by the presence of intracytoplasmic fibrillar -Synuclein (α-Syn) protein 
aggregates (Lewy Bodies, LB) in the remaining nigral neurons (Turturici et al., 2011). -Syn 
is a 140- amino acid neuronal protein probably involved in regulating cell differentiation, 
synaptic plasticity, and dopaminergic neurotransmission. The presence of large amounts of 
-syn aggregates in the presynaptic nerve terminals has been reported. It is plausible that 
either misfolded -Syn, or increased amounts of normal -syn, contribute to neurotoxicity 
in PD (Kramer & Schaeffer, 2007). The formation of an N-methylated derivative of -Syn, by 
the replacement of the Gly73 with sarcosine, resulted in reduced fibril formation and 
markedly reduces toxicity (Paleologou et al., 2005). -Syn peptide fragments that bind to full 
length -syn have also been studied as potential targets for inhibiting -syn aggregation. 
Peptides derived from the N-terminal of the non-amyloidogenic component (NAC) region 
of -syn can bind to the full length -syn and block the assembly of -syn into both early 
oligomers and mature amyloid-like fibrils. Furthermore, the addition of a polyarginine-
peptide delivery system has allowed the development of a cell permeable inhibitor of 
aggregation, the peptide RGGAVVTGRRRRR-amide, that inhibits iron-induced DNA 
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damage in cells transfected with ǂ-synuclein (A53T) (Paleologou et al., 2005). The other 
compounds which have been shown to inhibit - synuclein aggregation include melatonin 
(Sae-Ung et al., 2011), and statins (Bar-On et al., 2008).  
2.3 Huntington’s disease (HD) 
Inclusion bodies of aggregated mutant huntingtin protein (htt) fragments are a 
neuropathological hallmark of HD. The disease is caused by expansion of a CAG repeat in 
the Huntington’s gene coding for polyQ which leads to the formation of fibrillar protein 
aggregates and neuronal cell death. Preventing misfolding steps and thereby aggregation of 
the polyQ containing protein htt may represent an attractive therapeutic strategy to 
postpone the onset and progression of HD (Wyttenbach et al., 2002). Moreover expression of 
several molecular chaperones such as Hsp70, Hsp40, Hsp27, Hsp84, and Hsp105 have been 
shown to increase the solubility of polyQ proteins in Drosophila and mouse models of HD 
(Tarawneh & Galvin, 2010).  
Intracellular antibodies (intrabodies) which target polyQ protein and prevent its 
aggregation have been identified. Clumps of htt have also been seen in neuronal nucleus 
and cytoplasm in mice and monkey model of HD. Intrabodies created by injecting the virus 
into mice brain have been shown to mop up mutant proteins that drive neurodegeneration 
in HD (Wang et al., 2008). One of the first detectable signs of cellular dysfunction in strial 
medium spiny neurons in HD is the loss of cannibinoid G protein coupled receptors 
(GPCRs) (Glass et al., 2000). Activation of cannabinoid receptor 1 (CB1), in an invitro model 
of HD has been recently observed to confer significant level of protection against mutant htt 
induced cell death, (Scotter et al., 2010). Endocannabinoids act as neuromodulatory and 
neuroprotective cues by engaging type 1 cannabinoid receptors (CB1). Drugs that can 
activate CB1 receptor are expected to attenuate disease progression ( Blazquez et al., 2011). It 
has been suggested that the htt, aggregates may be cleared by autophagy (Rubinsztein et al., 
2005). In addition, administration of small molecules that promote autophagy has improved 
phenotypes in cell and animal models of HD (Ravikumar et al., 2004).  
Enhancing autophagy with rapamycin accelerated mutant htt clearance and improved cell 
viability. The levels of wild-type htt were not affected by these compounds, suggesting that 
autophagy plays a specific role in the clearance of aggregate-prone htt (Krainc, 2010). Recent 
studies have identified microtubule-associated protein light chain 3 proteins (LC3), 
interacting proteins, such as p62, that play a role in the autophagic clearance of protein 
aggregates (Komatsu et al., 2007). A multifunctional protein, p62 has been shown to bind 
ubiquitin and LC3; possibly providing a molecular shuttle for misfolded aggregated 
proteins to promote their clearance by autophagy (Bjorkoy et al., 2005). This data supports 
the idea that P62 induced autophagy may have significant potential for treating HD. Studies 
have also demonstrated that mutant htt interacts directly with the histone acetyltransferase 
(HAT) domain of the cyclic AMP response element binding protein (CBP) (Steffan et al., 
2001). Depletion of CBP enhances toxicity whereas over expression of CBP suppresses 
toxicity by mutant htt. Jeong et al. (2009) showed that acetylation of mutant htt by CBP leads 
to neuroprotection by improving clearance of the mutant protein. 
The green tea polyphenol (−) - epigallocatechin-3-gallate (EGCG), can potently inhibit htt 
aggregation in vitro and in a Drosophila model of HD (Ehrnhoefer et al., 2006). The agents 
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that can stabilize native conformation such as dimethyl sulfoxide (DMSO), glycerol, 
trimethylamine N-oxide (TMAO), and trehalose offer utility in preventing aggregation 
(Nagai and Popiel, 2008). 
2.4 Amyotrophic lateral sclerosis (ALS) 
Abnormal protein aggregates are seen in brain and spinal cord samples from patients with 
sporadic ALS, which suggests that protein misfolding and aggregation contribute to the 
pathogenesis of ALS, although a causative role remains controversial (Bosco et al., 2010; 
Kerman et al., 2010; Liu et al., 2009). The development of a vaccine or immunoglobulins to 
remove misfolded protein in ALS is a novel therapeutic strategy. There is emerging 
evidence for the existence of secretory pathways for superoxide dismutase (SOD1) mutant 
linked to ALS. Vaccination with SOD1 mutant protein in the ALS SOD1 transgenic mouse 
model delayed disease onset and significantly extended survival suggesting that 
immunization strategies should be considered as potential for treatment of familial ALS 
(Takeuchi et al., 2010).  
Arimoclomol an amplifier of heat shock protein expression is involved in cellular stress 
response, and has emerged as a potential therapeutic candidate in ALS in recent years. 
Treatment with arimoclomol was reported to improve survival and muscle function in a 
mouse model of motor neuron disease. Several single and multiple dose safety studies have 
been completed in healthy control subjects. A 3 month Phase IIa study in people with ALS 
demonstrated safety at dosages up to 300mg/day and another study is currently recruiting 
participants with familial ALS (Lanka et al., 2009). Up-regulation of endoplasmic reticulum 
chaperones and eukaryotic initiation factor 2 (eIF2) (Ilieva et al., 2007), activation of 
unfolded protein response cascades (Atkin et al., 2006) and ribosomal detachment resulting 
in endoplasmic reticulum distention and motor neuron shrinkage have all been 
demonstrated in pathological studies of sporadic ALS (Oyanagi et al., 2008). Increased levels 
of protein disulfide isomerase (PDI), an endoplasmic reticulum-localized chaperone 
molecule that promotes protein folding, have been found in cerebrospinal fluid of ALS 
(Atkin et al., 2006).  
These findings indicate an important role for endoplasmic reticulum stress and unfolded 
protein response dysregulation in the pathogenesis of ALS. Interestingly, lithium and 
valproic acid induce BiP and other endoplasmic reticulum chaperone proteins and reduce 
endoplasmic reticulum stress. Both of these drugs have been investigated in human studies 
without benefit (Aggarwal et al., 2010). 
3. Mitochondrial dysfunction 
Mitochondrial dysfunction has long been associated with neurodegenerative diseases 
(Burchell et al., 2010). Several lines of research suggest that mitochondrial abnormalities, 
including defects in oxidative phosphorylation, increased accumulation of mitochondrial 
DNA defects, impaired calcium influx, and accumulation of mutant proteins in 
mitochondria, are important cellular changes in both early and late-onset neurodegenerative 
diseases (Burchell et al., 2010). Therefore, one would predict that agents that alleviate 
mitochondrial dysfunction could be beneficial and exert neuroprotective effects (Burchell et 
al., 2010).  
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3.1 Alzheimer’s disease (AD) 
There is accumulating evidence suggesting that mitochondrial dysfunction occurs prior to 
the onset of symptoms in AD (Su et al., 2009). Mitochondria are exceptionally poised to play 
a crucial role in neuronal cell survival or neurodegeneration because they are regulators of 
both energy metabolism and apoptotic pathways (Su et al., 2009). In a recent study the 
mitochondria-targeted antioxidants (MTAs) MitoQ and SS31 and the anti-aging agent 
resveratrol were found to have a protective effect on neurons in a mouse model of AD 
(Manczak et al., 2010). In primary neurons from AǃPP transgenic mice, which were treated 
with MitoQ and SS31, neurite outgrowth significantly increased and cyclophilin D 
expression significantly decreased indicating potential of these drugs to treat AD (Manczak 
et al., 2010).  
Mitochondrial antioxidants acetyl-L-carnitine (ALCAR) and R-ǂ-lipoic acid (LA) reduced 
oxidative stress and mitochondrial abnormalities in cellular mouse models of AD and 
restored cognitive functions in aged rats (Aliev et al., 2009). A meta analysis of 21 double 
blind randomized, placebo controlled studies showed that ALCAR either improved 
cognitive deficits or delayed the progression of cognitive decline in AD (Montgomery et al., 
2003). 
Coenzyme Q10 (CoQ10) is essential for mitochondrial energy production. CoQ10 was 
observed to reduce oxidative stress and tau pathology in mice (Dumont et al., 2011), and 
inhibited ǃ-amyloid (ǃA) formation (Ono et al., 2005). CoQ10 treatment has also been shown 
to decrease brain oxidative stress, reduce ǃA plaque load, and improve cognitive 
performance in a transgenic mouse model of Alzheimer’s disease (Dumont et al., 2011). In a 
recent study dietary supplementation of carnosine an endogenous peptide with metal 
chelating and free radical scavenging properties was observed to completely rescue AD and 
aging related mitochondrial dysfunction and was suggested as a potential candidate for a 
combined therapeutic approach for the treatment of AD (Corona et al., 2011). 
3.2 Parkinson’s disease (PD) 
The most convincing evidence for the role of mitochondrial damage in PD comes from 
studies of rare familial forms of PD, in which genetic mutations linked to PD result in 
mitochondrial impairments and increased susceptibility to oxidative stress (Martin et al., 
2011). Parkin knockout mouse model demonstrate impaired mitochondrial activity and 
altered oxidative stress proteins in PD (Palacino et al., 2004). Further studies in this direction 
are likely to provide elaborate knowledge about mitochondrial dysfunction pathways in PD 
and help in developing new therapeutic strategies.  
A significant reduction in CoQ10 levels in mitochondria has been reported in the platelets of 
patients with PD, which directly correlates with a decrease in complex-I activity. CoQ10 
provides significant protection against MPTP-induced dopaminergic neuronal degeneration 
(Faust et al., 2009). The oral administration of CoQ10 in PD patients resulted in reduction of 
Unified Parkinson's Disease Rating Scale (UPDRS) scores (Shults et al., 2004). The 
mitochondrial targeted antioxidant MitoQ has been shown to help in preservation of 
mitochondrial function after glutathione depletion, this drug is currently in a phase II clinical 
trial for Parkinson’s disease (http://www.parkinsons.org.nz/news/protectstudy.asp). The 
other compounds which have shown promise in ameliorating the mitochondrial 
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dysfunction in experimental PD studies include creatine, lanosterol, melatonin, edaravone 
and trolox (Shim et al., 2011). However further studies are warranted before the clinical use 
of these drugs.  
3.3 Huntington’s disease (HD) 
Abnormal mitochondrial function, decreased respiratory enzyme complex activities, 
increased electron leakage, and increased Ca2+ entry have all been shown to play a 
significant role in the pathophysiology of many neurodegenerative disorders including HD. 
Current evidence from genetic models of HD including mutation of the Huntington gene 
(mhtt), supports the mitochondrial dysfunction as major cause of the disease, with 
respiratory chain impairment relegated to a late secondary event . HD is associated with 
significant defects in mitochondrial respiratory enzymes, including mitochondrial succinate 
dehydrogenase (SDH, complex II) and aconitase a transglutaminase substrate. Protein 
aggregates interfere with mitochondrial function, mitochondrial trafficking in axons, and 
result in mitochondrial fragmentation and inhibition of mitochondrial fusion. SDH 
inhibitors including 3-nitropropionic acid and malonate cause medium spiny neuronal loss 
and clinical and pathological features reminiscent of HD in rodents and non-human 
primates (Chaturvedi and Beal, 2008).  
High dose of CoQ10 significantly extends survival, improves motor performance and grip 
strength, and reduces brain atrophy in R6/2 HD mice. The combination of CoQ10 and 
minocycline in R6/2 mouse model of HD resulted in significantly improved behavioral 
measures, reduced neuropathological deficits, extended survival, and attenuated striatal 
neuron atrophy, as compared to either agent alone. Similarly, the combination of CoQ10 and 
remacemide resulted in significantly improved motor performance and increased survival 
in the R6/2 and the N-171–82Q transgenic mouse models of HD (Ferrante, 2002). These two 
compounds have been clinically tested separately and in combination in 340 patients with 
HD. Administration of CoQ10 resulted in a 14% decrease in disease progression while 
remacemide demonstrated no efficacy (Huntington Study Group, 2001). Creatine 
significantly improves survival, improves motor performance, increases brain ATP levels, 
and delays atrophy of striatal neurons and the formation of htt-positive aggregates in 
transgenic mice (Andreassen, 2001). Sirtuins (silent information regulators SIRT) are 
members of the NAD+-dependent histone deacetylase family of proteins in yeast, and play 
an important role in regulating mitochondrial function. Inhibition of sirtuins has been 
shown to suppress disease pathogenesis in Drosophila models of HD (Pallos, 2008).  
Reduced levels of peroxisome proliferator activated receptor gamma co activator alpha 
(PGC-1), a transcriptional regulator of several enzymes has been shown in the striatum of 
R6/2 HD mice. The PGC-1 pathway plays an important role in regulating cellular energy 
metabolism. PGC-1 induces mitochondrial biogenesis and respiration in muscle cells and 
regulates several aspects of adaptive thermogenesis by increasing expression of nuclear-
encoded electron transport chain components, metabolic enzymes, and uncoupling proteins. 
Increasing PGC-1 levels dramatically protect neural cells in culture from oxidative stress- 
mediated death (St –Pierre et al., 2006). Thus activity of PGC-1 pathways promises to be an 
effective therapeutic approach for mitochondrial disorders. Metformin can enhance the 
PGC-1 expression and mitochondrial biogenesis possibly at least in part via AMPK 
phosphorylation in the skeletal muscle (Suwa et al., 2006). The therapeutic effects of 
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metformin on HD warrants further studies. A recent study demonstrated that transcription 
factor peroxisome proliferator activated receptor (PPAR) plays a major role in energy 
homeostatis of HD. Rosiglitazone a potent agonist of PPAR has been shown to prevent 
mitochondrial dysfunction in mutant htt expressing cells and in R6/2 HD mice (Chiang et 
al., 2010; Quintanilla et al., 2008). These findings support the view that upregulation of 
PPARplays a major role in HD 
3.4 Amyotrophic lateral sclerosis (ALS) 
Mitochondrial and bioenergetic defects have been claimed to play vital role in ALS 
pathogenesis. Altered respiratory chain enzyme activities and CNS energy hypometabolism 
in spinal cord and motor cortex are the hallmark of ALS (Sasaki et al 2005). Swelling and 
vacuolar degeneration of mitochondria is a prominent finding prior to the onset of clinical 
deficits in experimental HD mice. Mutant SOD1 is found in the mitochondrial inter-
membrane space and binds to the inner mitochondrial membrane in the SOD1G93A mouse 
(Ahtoniemi et al., 2008) causing peroxidation of cardiolipin and alteration of anchor 
cytochrome c to the inner mitochondrial membrane which activates programmed cell death 
(Kirkinezos et al., 2004).  
Pramipexole a lipophilic cation that concentrates into brain and mitochondria significantly 
lowers oxidative stress, maintains mitochondrial function, and has neuroprotective effects 
independent of dopamine-receptor agonism. R+ pramipexole, prolonged survival of ALS 
SOD1 transgenic mice, and in a phase 2 study of 102 patients with ALS it was found to be 
safe and well tolerated (Cudkowicz et al., 2010). Motor decline seemed to lessen with 
increasing doses (Cudkowicz et al., 2010). These encouraging results in Phase II studies 
warrant further studies. Olesoxime (previously TRO19622) is a mitochondrial pore 
modulator that was discovered after screening about 40,000 compounds in an in-vitro motor 
neuron cell death assay (Bordet et al., 2007). In SOD1 transgenic mouse model, olesoxime 
showed a delayed onset and prolonged survival (Bordet et al., 2007). A phase 2/3 study of 
olesoxime is underway in Europe (NCT00868166). 
3.5 Multiple sclerosis (MS) 
There is increasing evidence implicating mitochondria in the pathogenesis of multiple 
sclerosis. Mitochondrial respiratory chain complex I and complex III activity is reduced in 
non-lesional motor cortex, where a number of nuclear DNA-encoded transcripts of 
mitochondrial proteins are decreased (Dutta et al., 2006). Interestingly, complex IV activity 
and mitochondrial DNA copy number are increased in chronic active lesion homogenates 
and within normal appearing grey matter neurons, respectively, possibly as a compensatory 
mechanism (Blokhin et al., 2008). Defects of mitochondrial respiratory chain complexes and 
depletion of mitochondria not only cause an energy deficit but may increase the 
susceptibility of axons to excitotoxic injury through impaired calcium handling capacity 
(Blokhin et al., 2008). The detoxification of mitochondrial superoxide by transfecting adeno 
associated virus containing manganese super oxide dismutase (SOD), led to a reduction in 
degeneration of mitochondrial structure (Qi et al., 2007). The Carboxyfullerene a fullerene 
compound that increased survival of mice lacking mitochondrial MnSOD (SOD-1) localized 
to mitochondria and reduced superoxide production. When combined with N-methyl D- 
aspartate (NMDA) receptor antagonist a fullerene derivative (ABS75) reduced axonal 
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degeneration and disease progression. The mitochondrial permeability transition pore 
which allows calcium efflux from mitochondria, when opened and is modulated during 
hypoxic preconditioning has been identified as a potential therapeutic target in MS (Forte et 
al., 2007) 
Polyunsaturated fatty acid (PUFA) and antioxidant deficiencies along with decreased 
cellular antioxidant defense mechanisms have been observed in MS patients. Both dietary 
antioxidants and PUFAs have the potential to diminish disease symptoms by targeting 
specific pathomechanisms and supporting recovery in MS (van Meeteren et al., 2005). 
Supplementation with long chain omega-3 PUFAs in MS patients and healthy controls 
decreased the secretion of the pro-inflammatory cytokines, IL-1b, TNF-ǂ, IL-2, and IFN-Ǆ by 
stimulated peripheral blood mononuclear cells as well as reduced secretion of the 
inflammatory eicosanoids such as, prostaglandin E2, and leukotriene B4 (LTB4), which are 
known to be increased in MS patients (Weinstock–Guttman et al., 2005). Thus dietary 
supplements which can modulate these eicosanoids help to reduce the severity of the 
disease and prevent recurrence, and in particular fish oil supplementation given together 
with vitamins C and E. can improve clinical outcome in patients with newly diagnosed MS. 
Although a few antioxidants showed some efficacy in animal models, there is limited and 
conflicting evidence of potential therapeutic effects of antioxidants such as vitamins C and E 
in treating MS. 
4. Inflammation 
Brain inflammation is a typical feature of neurodegenerative diseases and acute forms of 
brain injury. A large number of neurodegenerative diseases are associated with chronic 
inflammation, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral 
sclerosis, multiple sclerosis and all of the tauopathies, and age-related macular degeneration 
(Tansey and Goldberg, 2010). Considering the involvement of inflammatory processes in 
mechanism of neurodegeneration, and keeping in mind that activated microglia and 
astrocytes are a rich source of oxygen radicals, nitric oxide and neurotoxic and 
proinflammatory cytokines; anti-inflammatory drugs acting on these targets have the 
potential to exert beneficial effects in experimental and clinical neurodegenerative disorders. 
4.1 Alzheimer’s disease (AD) 
The brains of AD patients have increased concentrations of acute phase reactants, cytokines, 
and complement protein as compared to age-matched controls (Heng et al., 2007). In a 
prospective cohort study of subjects with AD, high baseline levels of tumor necrosis factor 
(TNF) alpha were also found to be associated with a 4-fold increase in the rate of cognitive 
decline (Holmes et al., 2009).  
Earlier studies have suggested a beneficial effect from non steroidal anti-inflammatory drugs 
(NSAIDs) in decreasing the risk of AD. Treatment with NSAIDs has been shown to decrease 
ǃ-amyloid and tau levels in animal models of AD (Yoshiyama et al., 2007). These effects of 
NSAID’s have been attributed to the inhibition of APP-associated -secretase (Sastre and 
Gentleman, 2010). It has been proposed that NSAIDs cause a delay in the onset or slow 
down progression of AD, through the inhibition of cyclooxygenase (COX) and 
lipooxygenases, leading to a decrease in prostaglandin synthesis and reactive oxygen 
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species formation (Leoutsakos et al., 2011). On the other hand, some other studies have 
suggested a possible deleterious effect of NSAIDs on cognition and an increase in neuronal 
damage (Breitner et al., 2011). The neurohormone melatonin was observed to exert 
inhibitory effects on ǃ-amyloid aggregation, oxidation, and inflammation in vitro, and 
showed behavioral improvement in animal model of AD. Although melatonin can improve 
mild cognition impairment, it is not a cure for AD (Olcese, 2009). Combination of ibuprofen 
with glutathione and lipoic acid has proven to be useful in controlling AD induced cerebral 
amyloid deposits and behavioral deterioration (Pinnen et al., 2011).  
4.2 Parkinson’s disease (PD) 
Systemic inflammation has been shown to promote microglial activation in PD, on the other 
hand genes implicated in PD may also influence inflammatory mediators. Over expression 
of wild-type ǂ-synuclein in neurons is associated with the activation of microglia, and the 
release of TNF, IL-1ǃ, IL-6, COX-2, and iNOS (Tarawneh & Galvin, 2010). Minocycline, a 
tetracycline derivative, has been shown to possess anti-inflammatory and anti-apoptotic 
properties, which reduces microglial activation and inhibit the release of potentially toxic 
cytokines in the striatal region of MPTP mice. Pretreatment with minocycline improved 
survival of dopaminergic neurons in animal models of PD (Peng et al., 2006). Based on the 
efficacy, safety and tolerability of minocycline in a randomized, double-blind, Phase II clinical 
trial (The NINDS NET -PD 2006), it has been recommended for long-term treatment of PD.  
NSAIDs have been associated with a 45% reduction in the risk of developing PD in one 
prospective study with 14 years of follow up (Wahner et al., 2007). On the other hand a case 
control study of 22,007 patients did not find evidence that NSAIDs use reduces PD (Driver 
et al., 2011). Triptolide, an active component of Tripterygium extracts, which possesses 
potent anti-inflammatory and immunosuppressive properties, exerts neuroprotective and 
neurotrophic activities in animal models of PD (Chen et al., 2010). Currently, the application 
of triptolide for PD is in preclinical stages. Similarly, the synthetic triterpenoid CDDO-Me, 
an inhibitor of NFKB attenuates production of TNF and other glial-derived inflammatory 
mediators has been shown to protect dopaminergic neurons (Trans et al., 2008). Glatiramer 
acetate (GA) is an artificial copolymer of a pool of peptides (45 ~ 100 amino acids, MW 4.7 ~ 
11 kDa) (Kipnis and Schwartz, 2002) which exerts anti-inflammatory effects through 
adaptive immunomodulation. Tsai (2007) suggested that it enhances the production of brain 
derived neuroprotective factor (BDNF) and has therapeutic potential for the treatment of 
familial PD. On the other hand immunomodulatory drugs including pargyline, selegiline 
(Deprenyl) and pentoxifylline, have all shown neuroprotective activity in both MPTP- (Liu 
and Hong, 2007) and the 6-OHDA rodent models of PD (Sanchez-Pernaute et al., 2004). 
Similarly, the glucocorticoid dexamethasone was shown to be protective against MPTP 
(Kurkowska-Jastrzebska et al., 2004). Other anti-inflammatory regimens such as steroids, 
which have been shown to be effective at arresting DA neuron loss in rodents, need further 
studies. At this time use of anti inflammatory drugs as a potential preventive therapeutic 
measure in PD remains but a promising possibility.  
4.3 Huntington’s disease (HD) 
Neuroinflammation is a prominent feature associated with HD and may constitute a novel 
target for neuroprotection. Increased expression of several key inflammatory mediators, 
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including IL-6, IL-8, and MMP9, in the striatum, cortex and cerebellum in experimental and 
clinical HD has been reported (Silvestroni, 2009). Treatment of quinolic acid induced HD 
rats with minocyline resulted in the attenuation of inflammation, and reduction of striatal 
lesions (Ryu et al., 2006). In a first open-label safety and efficacy trial, 10 out of 14 HD 
patients treated with minocycline (100mgday–1) showed an improvement in their Unified 
HD Rating (Bonelli et al., 2004). In striking disagreement with this study, subsequent studies 
using higher doses of minocycline (200mgday–1) showed good tolerance and apparent 
safety, but failed to exhibit any improvement in HD features (Reynolds, 2007). Besides these 
conflicting results, the safety of minocycline has recently been questioned when two-thirds 
of subjects who were administered minocycline discontinued the drug after developing 
serious hyperpigmentation only 1 year into the 5-year treatment regime (Reynolds, 2007). 
Treatment with acetylsalicylate or rofecoxib in transgenic mice model of HD failed to show 
any beneficial effects (Norfus et al., 2004). Dexamethasone treatment (4mg daily for 20 days 
followed by 8mg daily for an additional 20 days) in HD patients has demonstrated 
improvement of abnormal involuntary movements, and manual dexterity, with no observable 
side-effects (Bonnucelli et al., 1992). Accumulating evidence suggests that changes in the 
immune system may critically contribute to the pathology of HD. However, the nature of this 
contribution remains unclear, to the extent that it is not even known whether the immune 
activation has a beneficial or detrimental role in HD patients (Soulet and Cicchetti, 2011).  
4.4 Amyotrophic lateral sclerosis (ALS) 
Inflammation has been shown to play a critical role in the pathogenesis of ALS. Markers of 
inflammation, including microglial stimulating factors and pro-inflammatory cytokines, 
such as TNF alpha and FasL are increased in ALS (Kiaei et al., 2006).Several places in the 
inflammatory events that appear to accompany ALS might be amenable to drug action. 
Animal experiments have suggested that Cox 2 inhibitors might be of use in ALS, but a 
clinical trial of a direct inhibitor of Cox2 has failed to give a definite answer.  
Lenalidomide a potent immunomodulatory agent with abiity to down regulate pro- 
inflammatory cytokines prolong survival in the transgenic mouse model of ALS (G93A 
mice) by destabilizing DNA coding for TNFǂ and other cytokines (Kiaei, 2006). 
Lenalidomide significantly attenuated neuronal loss, improved motor performance, and 
survival. These data encourage clinical evaluation of lenalidomide to slow or block 
progression of ALS (Neymotin et al 2009). Pioglitazone, a peroxisome proliferator-activated 
receptor-gamma (PPAR ) agonist with anti-inflammatory properties, has been shown to 
improve motor performance, delay weight loss, attenuate motor neuron loss, and extend 
survival of transgenic mouse models of ALS (Kiaei, 2005). A clinical trial for safety and 
efficacy of pioglitazone in ALS patients - models is expected to be  completed  by the end of 
2011. Although immune modulators/anti inflammatory drugs including minocycline, 
celecoxib, rofecoxib, and sulindac showed protection in mouse models of ALS, but these 
drugs failed in human ALS trials (Gordon et al., 2007).  
4.5 Multiple sclerosis (MS) 
Multiple Sclerosis is an idiopathic disease in which the body's immune response attacks the 
central nervous system resulting in demyelination. Although its exact etiology and 
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pathogenesis are still unclear, there is much evidence to suggest the involvement of T cell 
triggered inflammation. In MS, peripheral T cells gain entry into the brain via the BBB, 
recognize myelin as foreign body and attack it as if it were an invading virus. This triggers 
inflammatory processes and stimulates other immune cells and soluble factors such as 
cytokines and antibodies (Leary and Thompson, 2005). 
In a large clinical trial, immunomodulatory drug, glatiramer acetate was found to be 
efficient in the treatment of relapsing remitting multiple sclerosis, however the trial had to 
be terminated prematurely because the drug failed to stop disease progression after two 
years (Wolinsky et al., 2007). The results of trials with the immunomodulatory drug, 
interferon beta (IFN beta), in patients with MS were also disappointing (Montalban, 2004). 
Recently, a single-center, phase two pilot study with interferon beta-1b on primary 
progressive MS disease showed no effect on sustained disability assessed by expanded 
disability status scale (EDSS), but surprisingly revealed statistically significant differences 
for the multiple sclerosis functional composite score and for T1 and T2 lesion volume 
(Montalban et al., 2009). Studies on humanized monoclonal antibody, alemtuzumab 
(Campath-1H), which induces the cytolysis of CD52 positive cells leading to a T cell 
depletion is highly effective in reducing relapse rate, MRI lesion load and disease 
progression in relapsing remitting multiple sclerosis (The CAMMS223 Trial 2008), However, 
it does not seem to protect from disease progression once patients have progressed to 
secondary progressive stage (SPMS) (Coles et al., 2006). Laquinimod (ABR-215062) is 
another orally administered investigational agent that, in animal models of MS, has been 
shown to decrease leukocyte infiltration into the central nervous system and to induce a 
shift from T-helper type 1 (Th1; proinflammatory) cells to Th2/3 (anti-inflammatory) cells 
(Miron et al., 2008). Phase III clinical trials suggested a significant activity of laquinimod (as 
shown on MRI measures) against the relapsing form of MS (Miron et al., 2008). The agent 
also appears to exhibit synergistic immune modulating effects when given with interferon 
therapy (Miron et al., 2008).  
5. Oxidative stress 
Neuronal cells in the brain are highly sensitive to oxidative stress due to their large 
dependence on oxidative phosphorylation for energy, normal functioning and survival. In 
brain the demand for oxygen consumption is extremely high with 1-2% of the oxygen being 
converted into superoxide anion radicals (O2) and hydrogen peroxide, leading to oxidative 
stress (Moura et al., 2010). Oxidative stress results when there is an imbalance of reactive 
oxygen species (ROS) production and availability of endogenous antioxidants to scavenge 
the ROS. Generation of high levels of ROS, and down regulation of anti-oxidant 
mechanisms, results in neuronal cell death in neurodegenerative diseases (Farooqui and 
Farooqui, 2009). The role of oxidative stress and use of antioxidants as neuroprotective 
agents in some of the common neurodegenerative disorders is discussed below:  
5.1 Alzheimer’s disease (AD) 
Oxidative stress has been associated in beta amyloid (Aǃ) toxicity; It is clearly evident from 
in vitro studies that oxidation of soluble Aǃ promotes its transformation into the aggregated 
form creating a vicious cycle of aggregation and oxidative damage (Lee, 2010). There is 
ample evidence to suggest that amyloidal aggregation can be inhibited by antioxidants, and 
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free radical scavengers, such as vitamin E and propyl gallate, have been shown to protect 
neuronal cells against Aǃ toxicity (Behl, 1999).The most common antioxidant vitamin E has 
been found to delay clinical progression in AD patients from moderate to severe 
impairment, although no cognitive benefit was found (Wyttenbach et al., 2000). On the other 
hand Masaki et al. (2000), reported that vitamin E improves cognitive performance in AD. 
According to some recent reports antioxidant supplementation has not been effective for the 
treatment of AD (Mecocci and Polidori, 2011). In spite of these conflicting reports there 
remains considerable interest in vitamin E, and an important ongoing study (Dysken, 2010), 
is expected to clarify these doubts.  
Recent studies have shown that melatonin levels are lower in AD patients compared to age-
matched control subjects (Mahlberg et al., 2008). Treatment with melatonin provides 
protection against AD by inhibiting Aǃ-induced toxicity (Zhou et al., 2008; Wang, 2009). 
However there is insufficient evidence to support the effectiveness of melatonin for 
managing cognitive impairment in AD (Jansen et al., 2006). Further clinical phase II trial to 
determine the effect of melatonin on cognitive function in mild cognitive impaired (MCI) 
patients is presently undergoing (ClinicalTrials.gov Identifier: NCT00544791).  
Statins by virtue of their hypocholestremic, antioxidant and anti inflammatory properties 
have been shown to lower Aǃ production and to reduce Aǃ-mediated neurotoxicity. On the 
contrary no significant clinical benefit on cognition or global functioning was shown by 
atorvastatin in a phase 3 clinical trial in patients with mild-to-moderate AD already taking 
donepezil (Feldman et al., 2010). Another clinical trial, to test the effectiveness of statins in 
prevention and therapy of Alzheimer’s disease, is ongoing (Mangialasche et al., 2010).  
Recent experimental studies using a wide range of antioxidants including P- P methoxy – 
diphenyl diselenide (Pinton et al., 2011), S allyl cysteine (Javed et al., 2011), conjugates of 
ibuprofen and glutathione (Pinnen et al., 2011), tirilazad (Youdim et al., 2004), Ibuprofen 
and lipoic acid (Distefano et al., 2010), and chlorogenic acid (Kwon et al., 2010), have shown 
neuroprotective effects in animal models of AD. On the other hand mitochondria specific 
antioxidants such as acetyl-L-carnitine and R-alpha lipoic acid have been suggested to be 
beneficial for treatments for AD (Palacios et al., 2011). Further clinical studies are warranted 
to establish the therapeutic efficacy of these drugs in AD.  
5.2 Parkinson’s disease (PD) 
Oxidative damage to proteins, lipids, and nucleic acids has been found in the substantia 
nigra of patients with PD (Fasano, 2006). The metabolism of dopamine (DA) itself creates a 
favorable environment for oxidative damage through intermediates such as DA-quinone 
and 3, 4- dihydroxy phenylacetaldehyde (Jackson and Smeyne , 2005). On the other hand 
reduced plasma levels of anti-oxidants such as glutathione and uric acid have been reported 
in PD patients (Elokda et al., 2010). 
An open label study of Vitamin E and Vitamin C, suggested that these antioxidants delay 
the need to initiate levodopa therapy for the treatment of PD by 2.5 years (Fahn et al., 1992), 
while other randomized placebo controlled trials showed no disease-modifying effect for 
Vitamin E, (Shoulson, 1998), but a modest protective effect and slowing of disease 
progression was observed when vitamin E was given with with Deprenyl, (Olanow, 1995). 
The use of glutathione (600 mg twice daily) in patients with PD resulted in significant 
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decrease in their disability scores (Sechi, 1996). Selegeline and rosagiline the inhibitors of 
monoamine oxidase B (MAOB) also significantly delayed the onset of L dopa in PD patients. 
Oral Coenzyme Q10 (CoQ10), a cofactor in electron transport chain in mitochondria, was 
shown to slow motor deterioration, and improve activities of daily living in patients with 
mild PD (Shults, 2002). Studies on beneficial effect of lycopene supplementation suggest its 
therapeutic potential in PD (Kaur et al., 2011). A small number of controlled trials indicate 
that melatonin is useful to treat disturbed sleep in PD (Medeiros et al., 2007), particularly 
rapid eye movement-associated sleep behavior disorder (Aurora et al., 2010). Melatonin and 
the recently introduced melatonergic agents (ramelteon, agomelatine) merit further 
investigations (Srinivasan et al., 2011).  
5.3 Huntington’s disease (HD) 
Oxidative stress has been shown to play an important role in the pathogenesis of HD. 
Elevated levels of oxidative damage products such as malondialdehyde, 8 hydroxy-
guanosine, 3 nitrotyrosine and heme oxygenase in the brain of HD patients and increased 
free radical production in animal models indicates the involvement of oxidative stress either 
as a causative event, or as a secondary constituent of the cell death cascade. Recently Lee et 
al (2011), observed an increase in the level of 4 hydroxynonenal (4 HNE) a useful marker for 
the oxidative stress in both human and animal models of HD, suggesting that the lipid 
peroxidation pathway may be a novel therapeutic target for preventing oxidative damage in 
HD.  
Treatment with CoQ10 was associated with reduced levels of 8-hydroxyguanosine (a 
marker of oxidative damage) and improved survival in experimental model of HD mice. In 
a multicenter, blinded, randomized study on HD patients administered 300 mg CoQ10 
slowed the decline of total functional capacity (Huntington Study Group 2001). A higher 
dose of coenzyme Q10 (2400 mg) for HD, is now in phase III of clinical trial (NCT00608881). 
Results of a recent study using antioxidant dimebon (the old Russian cold medicine), 
showed that 60 mg per day was safe and well tolerated and improved cognition in 
individuals with HD (Kieburtz, 2010). However in a clinical trial on late stage HD patients 
dimebon failed to show a significant improvement in cognition or global functioning.  
The antioxidant response element (ARE) signaling pathway is an important pathway 
involved in antioxidant and anti-inflammatory responses (Johnson et al., 2008). The ARE is 
activated through the binding of its transcription factor, Nrf2 (NF-E2-related factor 2). In 
addition to the typical induction of detoxification enzymes, Nrf2-ARE activation results in 
increased cellular energy and redox potential, inhibitory neurotransmitter signaling, and 
metabolic processes (Nguyen et al., 2004). Synthetic triterpenoids, which are derived from 2-
Cyano-3,12-Dioxooleana1,9-Dien-28-Oic acid (CDDO) have been shown to up-regulate 
Nrf2/ARE induced genes in the brain and peripheral tissues, reduce oxidative stress, 
improve motor impairment and increase longevity in HD mice (Stack 2010). This compound 
showed a great potential for treatment of HD. Eriodictyol, a flavonoid found in citrus fruits, 
induces the nuclear translocation of Nrf2, enhances the expression of heme-oxygenase-1 
(HO-1) and quinone oxidoreductase 1 (NQO-1), and increases the levels of endogenous 
antioxidant glutathione (Johnson et al., 2009), these findings suggest its potential use for the 
treatment for HD and other neurodegenerative disorders.  
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5.4 Amyotrophic lateral sclerosis (ALS) 
Oxidative damage mediated by toxic free radicals has been implicated in the pathogenesis of 
ALS (Graf et al 2005). Abundant evidence of oxidative stress has been found in autopsy 
specimens of ALS, including elevated protein carbonyl levels, increased 3-nitrotyrosine 
levels, 8-hydroxy-2-deoxyguanosine (a marker for oxidative DNA damage) and 4 HNE 
levels (an indicator of lipid peroxidation) (Barber et al., 2006). 
About 20% of familial ALS is caused by a genetic defect in an antioxidant enzyme called 
super oxide dismutase –1 (SOD-1). A study on AEOL 10150, a manganoporphyrin 
antioxidant that catalytically neutralizes superoxide, hydrogen peroxide, and peroxynitrite, 
and inhibits lipid peroxidation showed that administration of this drug to SOD1G93A 
transgenic mice at symptom onset improved the survival period by 196% (Crow et al., 2005). 
In 2005 a phase I single dose escalating study of AEOL 10150 showed that the drug was well 
tolerated with no serious adverse events [www.rideforlife.com]. Clinical trials with 
promising second-generation antioxidant, edavarone which was shown to slow motor 
decline and neuron degeneration in a - a mice model of ALS are underway (Kuzma-
Kozakiewicz and Kwiecinski, 2011). A recent study utilizing dietary supplementation with S 
adenosyl methionine (SAM) altered the course of motor neuron pathology in G93A mutant 
SOD1 mice by preventing loss of motor neurons and reducing gliosis, SOD-1 aggregation, 
protein carbonylation, and induction of antioxidant activity (Suchy et al., 2010).  
5.5 Multiple sclerosis (MS) 
It has been suggested that mitochondrial injury and subsequent energy failure is a major 
factor driving axonal injury in MS patients (Witte et al., 2010). As the mitochondrial 
proteins and DNA are highly vulnerable to oxidative damage (Higgins et al., 2010), it has 
been proposed that free radical-mediated mechanisms may lead to mitochondrial injury 
in MS (van Horssen et al., 2011). Oxidized lipids and oxidized DNA have been detected 
in the brain tissues from patients with MS (Quin et al., 2007). Results from a recent study 
(Haider et al., 2011), on autopsy material from HD patients provide extensive evidence 
for an important role of oxidative damage in the pathogenesis of demyelination and 
neurodegeneration in MS.  
Treatment with lipoic acid and anti-acrolein compound hydrazine both potent antioxidants, 
were observed to reduce axonal injury in experimental models of MS (Chaudhary et al., 
2011). Recently C-Phycocyanin and saffron naturally occurring antioxidants improved 
experimental Autoimmune Encephalitis (EAE) and peripheral blood mononuclear cells from 
MS patients (Penton -Rol et al., 2011; Ghazavi et al., 2009). Viral mediated delivery of 
antioxidant genes of superoxide dismutase and catalase in EAE mice has also been observed 
to suppress neuronal and axonal loss (Qi et al., 2007). Inosine is a widely distributed 
nucleoside in the body and is a potent scavenger of free radicals. Administration of inosine 
in MS patients resulted in a significant decrease in the number of lesions and improved 
disability status (Markowitz et al., 2009). Erythropoietin (Epo), a hematopoietic growth 
factor and an antioxidant, showed clinical and electrophysiological improvement of  
motor function as well as improved cognitive performance in MS patients (Ehrenreich et al., 
2007). 
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6. Targeting glutamate excitotoxicity 
Excessive activation of glutamate receptors by excitatory amino acids leads to a number of 
deleterious consequences, including impairment of calcium buffering, generation of free 
radicals, activation of the mitochondrial permeability transition and secondary excitotoxicity 
(Berliocchi et al., 2005). A pivotal role for excitotoxicity in neurodegenerative diseases is 
gaining increasingly more acceptance (Kim et al., 2011). Progress in the use of anti-
excitotoxic drugs for the treatment of neurodegenerative disorders is discussed below.  
6.1 Alzheimer’s disease (AD) 
Several studies have linked tau and amyloid aggregation to glutamate mediated toxicity and 
clearly suggest the involvement of N-methyl-D–Aspartate (NMDA) receptor subunits (NR1 
and NR2) in the pathogenesis of AD (Koutsilieri and Riederer, 2007). Alzheimer’s disease is 
associated with reduced levels of two mRNA isoform subsets of the NR1 receptor and 
changes in the expression of NR2A and NR2B in the superior temporal cortex, cingulate 
cortex and hippocampus (Hynd et al., 2004). The presence of presenilin-1 in a 
macromolecular complex with NR1 and NR2A further supports a role for excitotoxicity in 
AD (Saura et al., 2004). 
Memantine is an uncompetitive NMDA receptor antagonist that can decrease pathological 
activation of NMDA receptors without affecting physiological NMDA receptor activity 
(Farlow, 2008). Memantine is associated with functional improvement in AD patients and 
has been approved by FDA for the treatment of AD (Farlow, 2008). Latrepirdine (Dimebon), 
a nonselective antihistamine and weak NMDA receptor blocker was found to have 
beneficial effects in animal models of AD (Santamaría et al., 2001). It has also been shown to 
enhance mitochondrial function (Wyttenbach et al., 2002). In a clinical trial (Goswami et al., 
2006), on 183 patients with mild to moderate AD, latrepirdine, improved performance on 
the primary cognitive outcome, behavioral activities of daily living, and global function. The 
most common side effects were dry mouth and depressed mood, in some patients. 
However, a recent phase III AD trial of Dimebon in 598 patients did not show any 
significant improvement in primary or secondary outcomes (Bezprozvanny, 2010).  
6.2 Parkinson’s disease (PD) 
Brain glutamate over activity is well documented in Parkinson’s disease (Morin et al., 2010). 
Studies on dopamine denervated rats and MPTP-treated Parkinsonian monkeys have clearly 
provided insight into the relative abundance of different NMDA subunits in the striatum. 
Dopamine depletion in the 6-OHDA rat models, and MPTP primate models results in 
relative decrease in the abundance of NMDA receptor subtype 1 (NR1) and subtype 2B 
(NR2B) subunits in the synaptosomal membranes, which is restored by chronic levodopa 
therapy (Dunah, 2000; Hallett et al., 2005). Since stimulation of NR2B-containing NMDA 
receptors contributes to the generation of Parkinsonian symptoms (Hallett and Standaert, 
2004), NR2B-selective NMDA receptor antagonists may be therapeutically beneficial for 
Parkinsonian patients. Prior administration of NMDA receptor antagonist dizocilpine 
suppresses the dopa-induced increase in glutamate in 6-hydroxydopamine-lesioned rats 
and may therefore offer neuroprotection (Jonkers, 2002). 
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Several NMDA antagonists have been studied in PD (Tarawneh and Galvin, 2010). Both 
amantidine and dextromethorphan have antidyskinetic effects. Amantidine has been 
associated with increased lifespan (Uitti, 1996; Verhagen, 1998). Selective NMDA receptor 
antagonists, such as ifenprodil and CP-101,606, have been developed in an attempt to avoid 
the side effects of non-selective blockers. Ifenprodil, has anti-Parkinsonian actions in rat and, 
and nonhuman primates (Nash and Brotchie, 2002). CP-101,606 reduced Parkinsonian 
symptoms, in both haloperidol-treated rats, and MPTP-lesioned nonhuman primates 
(Steece, 2000). Pretreatment of 6-OHDA lesioned rats with 4-trifluoromethoxy-N-(2-
trifluoromethyl-benzyl)-benzamidine (BZAD-01), a novel selective inhibitor of the NMDA 
NR1A/2B receptor, significantly reduced the amount of dopaminergic cell loss and 
significantly improved all behavioral measures (Leaver et al., 2008). When given in 
combination with levodopa-carbidopa, the NMDA-antagonist remacemide, has been shown 
to reduce parkinsonism in rodent and monkey models of Parkinson’s disease (Greenamyre, 
1994). A clinical study confirmed that remacemide is safe and well tolerated in PD patients 
who are treated with L–DOPA (Clarke, 2001).  
The simultaneous blockade of AMPA (ǂ-amino-3-hydroxy-5-methyl-4- isoxazolepropionic 
acid) and NMDA receptor offers substantially greater reduction in the response alterations 
induced by levodopa than inhibition of either of these receptors alone in both rat and 
primate models of PD. Simultaneous blockade of the AMPA receptors with GYKI-47261 and 
NMDA receptor with amantadine or MK-801 resulted in significant reductions in levodopa- 
induced dyskinesias in a primate model, while the wearing-off dyskinesias were completely 
ameliorated in rat models of PD (Bibbiani, 2005). Treatment with NMDA glutamate receptor 
antagonist memantine for 52 weeks resulted in the improvements in cognitive functions and 
stabilization of motor impairments in PD patients (Litivinenko et al., 2010).  
6.3 Huntington’s disease (HD) 
The major hypothesis driving HD synaptic research is the excitability of medium spiny 
projection neurons (MSNs). Injections of excitatory amino acids into the striatum of rodents, 
and primates results in neuronal death and a neurologic phenotype similar to that of 
Huntington’s disease. Intrastriatal injections of NMDA glutamate agonists, such as 
quinolinic acid, have been used to create animal models of HD. Animal models and human 
studies show evidence of decreased glutamate receptors, in particular the mGluR2 subtypes, 
down-regulation of the GLT-1 glial glutamate transporter, and increased sensitization of 
NMDA receptors (Leegwater and Cha, 2004). Since excitotoxicity is known to be involved in 
the development of HD, approaches to reduce extra synaptic glutamate signaling have been 
explored and include modulation of NR2 B signaling (Heng et al., 2009), lowering glutamate 
receptor activation with NMDA receptor antagonists (Ketamine and memantine), and 
modulating the interplay of glutamate and dopamine on MSNs (Andre et al., 2010). The 
efficacy of memantine in slowing down the rate of progression of HD was studied in a two 
year, open and multicenter trial with promising results (Beister et al., 2004).  
Cannabinoid-derived drugs also hold great promise in protecting neurons from glutamate 
mediated toxicity. Activation of neuronal CB (1) or CB (2) cannabinoid receptors attenuates 
excitotoxic glutamatergic neurotransmission and triggers prosurvival signaling pathways. 
The administration of CB (2) receptor-selective agonists reduced neuroinflammation, brain 
edema, striatal neuronal loss and motor symptoms in wild-type mouse models subjected to 
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excitotoxicity (Palazuelos, 2009). Treatment with the analogue of the antiglutamatergic agent 
and the tryptophan metabolite kynurenic acid (KYNA), in transgenic mouse model of HD 
resulted in prolonged survival, reduction in hypo-locomotion, and prevention of atrophy of 
the striatal neurons (Zadori et al., 2011).  
6.4 Amyotrophic lateral sclerosis (ALS) 
Glutamate-mediated excitotoxicity arising from repetitive firing or elevation of intracellular 
calcium by calcium permeable glutamate receptors has long been postulated to have an 
important role in motor neuron degeneration in ALS (Rowland and Schneider, 2001). 
Glutamate levels are increased in cerebrospinal fluid of patients with sporadic ALS 
(Rothstein et al 1990) and clearance of glutamate from neuromuscular synapses is 
diminished in patients with ALS due to loss of the astroglial glutamate transporter EAAT2 
(excitatory amino acid transporter 2), that is of major importance for synaptic glutamate 
reuptake (Rothstein et al., 1995). 
Cephalosporins increase EAAT2 promoter activity and protect motor neurons from 
glutamate toxicity in organotypic spinal cord slice cultures of rats (Rothstein et al., 1993). 
Controversial but mainly negative data on the efficacy of cephalosporins in ALS have been 
published (Norris, 1994). However, gabapentin, lamotrigine, and topiramate, and other 
agents known to alter glutamate synthesis and release, appeared promising in pre-clinical 
studies (Maragakis et al., 2003) but showed no benefit in ALS patients (Cudkowicz et al., 
2003). Beta-lactam antibiotics exert neuroprotective effects by up-regulating GLT-1 receptors 
in vitro and in vivo in normal rats (Rothstein et al., 1995) and in transgenic ALS mice treated 
with ceftriaxone (Rothstein et al., 2005). Harvey and Martz (2007) have reported prolonged 
treatment with atovaquone, an antimalaric drug, showed a persistent disease remission. 
This observation confirms the previous reports of a possible therapeutic effect of beta-lactam 
antibiotics in ALS. A double blind placebo controlled clinical trial on about 600 patients 
using a β lactam antibiotic ceftriaxone which is a safe EAAT2 expression enhancer, is  
being carried out in the United States of America (NCT00349622) since July 2006. 
 Final data collection for the primary outcome measure (survival and rate of change in 
ALSFRSr – stage 3) will be available in March 2012. Talampanel (8-methyl-7H-1,3-
dioxolo(2,3)benzodiazepine), is a noncompetitive modulator of AMPA glutamate receptors 
which is under development as an antiepileptic agent, has been shown to prolong survival 
of SOD1G93A ALS mouse (Traynor et al., 2006). The ALS Functional Rating Scale-revised 
(ALSFRS-r) scores declined at a slower rate in a 9-month phase II study of talampanel in 60 
patients (Traynor et al., 2006). The inhibitor of presynaptic glutamate release, riluzole, is 
currently the only drug that has shown efficacy in a phase 3 study in ALS patients (Zinman 
and Cudkowicz,  2011). On the other hand memantine was well tolerated in combination 
with riluzole in patients with ALS resulting in some improvement in function rating of 
disease (Levine et al., 2010).  
6.5 Multiple sclerosis (MS) 
Glutamate excitotoxicity mediated by the AMPA /kainate type of glutamate receptors not 
only damage neurons but also the myelin producing of oligodendrocytes of the CNS. In MS, 
oligodendrocytes and some axons are lost as a result of excessive relaease of glutamate by 
activated immune cells. It has been suggested that glutamate activates immune cells and 
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inflammation and contributes to lesion formation in MS (Gonsette, 2008). The hypothesis 
that the excitatory neurotransmitter glutamate contributes to axonal damage has been 
strengthened by several studies demonstrating the neuroprotective effects of  
AMPA receptor antagonists such as NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-
benzo(F)quinoxaline) in animals (Pitt et al., 2003). In addition, memantine, a NMDA 
antagonist currently available for the management of Alzheimer's disease, ameliorates 
disability in experimental autoimmune encephalomyelitis-affected rats, raising the 
possibility of its neuroprotective effect in MS (Wallström et al., 1996). The protective effects 
of glutamate antagonists are important, especially as it has been hypothesized that 
AMPA/kainate receptors become the primary mediators of axonal injury during prolonged 
and intensified injury exposure in the chronic phase (Ouardouz et al., 2006) suggesting the 
possibility of a potential benefit in targeting these receptors. Riluzole inhibits the release of 
glutamate from nerve terminals and modulates the activities of both kainate and NMDA 
receptors is presently undergoing a clinical trial alone and in combination with interferon ǃ 
(NCT 00501943) at University of California, USA.  
Another promising compound for treating MS is minocycline, which has been found to be 
protective in many neurodegenerative diseases (Fong et al., 2008). Experimental studies 
using both invitro (Defaux et al., 2011) and invivo (Chen et al., 2010) models of MS showed 
protective effects of minocycline. Combination of minocycline with methylprednisolone and 
atorvastatin was observed to synergistically suppress EAE severity in mice (Chen et al 2010). 
At the same time results of a clinical trial, involving minocyline alone and in combination 
with glatiramer acetate in patients with MS, showed minocyline to be safe and well 
tolerated with a reduction in the relapse rate (Zhang et al., 2008). The encouraging results 
from the animal models and clinical experiments on minocycline make it a promising 
candidate for MS treatment whether used alone or combined with other drugs (Chen, 2011). 
7. Apoptosis 
Apoptosis is a form of cell death in which programmed sequence of events lead to 
elimination of cells without releasing harmful substances in surrounding area. It plays a 
crucial role in developing and maintaining health by eliminating old cells, unnecessary cells 
and unhealthy cells. However premature apoptosis and/or an aberration in apoptosis 
regulation may lead to degenerative disorders. Neuronal apoptosis can be induced both in 
vivo and in vitro by different stimuli including oxidative stress, calcium toxicity, 
excitotoxicity, inhibition of the mitochondrial respiratory chain, and deficiency of survival 
factors which may contribute to disorders including Alzheimer’s disease, Huntington’s 
disease, Parkinson’s disease, amyotrophic lateral sclerosis and multiple sclerosis. Inhibition 
of apoptosis could constitute a suitable therapeutic strategy for delaying the progression of 
neurodegenerative disease (Sureda et al., 2011).  
7.1 Alzheimer’s disease (AD) 
Extensive evidence showed that apoptosis is involved in neuronal loss in AD. Postmortem 
analysis of AD brain showed DNA fragmentation in neurons and glia of hippocampus and 
cortex as detected by TdT-mediated dUTP nick end labeling (TUNEL) (Vila and 
Przedborski, 2003). Rohn, et al. (2002) demonstrated the activation of mitochondrial and 
receptor-mediated apoptotic pathways in AD hippocampal brain sections wherein active 
www.intechopen.com
 
Neurodegeneration 
 
172 
caspase-9 was co-localized with active caspase-8. Recently, a marked co-localization of 
pathological hyperphosphorylated tau, cleaved caspase-3 and caspase-6 has been reported 
in TUNEL-positive neurons in the brain stem of AD patients (Wai et al., 2009). Furthermore, 
in vitro studies have shown that amyloid beta protein (A) provokes a significant down 
regulation of antiapoptotic proteins such as Bcl-2, Bcl-xl and Bcl-w and a significant up-
regulation of pro-apoptotic proteins such as bax (Yao et al., 2005). 
The activation of Poly ADP-ribose polymerase (PARP) plays a critical role in caspase-
independent apoptosis. Therefore, PARP inhibitors represent one possible therapeutic 
strategy in AD. Insulin like growth factor-binding protein-3 (IGFBP-3) modulates cell 
growth and survival. Humanin (HN) a peptide and IGFBP3 coactivator significantly 
inhibited neuronal cell death induced by familial Alzheimer’s disease mutant gene and 
amyloid ǃ (Aβ) (Ikonen et al., 2003). Thus HN acts as AD related survival factor by 
interacting with IGFBP-3. Recently, it has been suggested that a potent humanin derivative 
may be a promising alternative strategy for AD therapy (Matsuoka & Hashimoto, 2009). 
Pycnogenol (PYC), a potent antioxidant suppressed caspase-3 activation, DNA 
fragmentation, PARP cleavage, and eventually protected against Aǃ-induced apoptosis in 
animal model of AD. PYC is a promising candidate for clinical trials in AD (Ishrat et al., 
2009).  
Invitro studies demonstrated antiapoptotic activity of the endogenous antioxidants 
geniposide and estrogen (Liu et al., 2009). Recently Puerarin, a phytoestrogen was observed 
to prevent Aǃ-induced neurotoxicity through inhibiting neuronal apoptosis. Further studies 
are warranted to study these antiapoptotic drugs for their, preventive or therapeutic efficacy 
in AD (Xing et al., 2011). 
Melatonin is a natural hormone secreted by the pineal gland. In vitro experiments showed 
that Aǃ−treated cultures exhibited characteristic features of apoptosis, and melatonin 
attenuated Aǃ-induced apoptosis and activated the survival signal pathways stabilizing 
mitochondrial function by acting as anti-apoptotic Bcl-2 family modulator (Jang et al., 2005). 
Melatonin significantly delays the development of the signs of AD, prevents cognitive 
impairment, and ameliorates sundowning in AD patients (Gehrman et al., 2009). 
7.2 Parkinson’s disease (PD) 
Accumulating evidence suggests that the molecular and biochemical pathways of apoptosis 
are involved in dopaminergic cell death in PD. This evidence includes the activation of the 
mitogen activated protein (MAP) kinase pathway, the induction of Bax, prostate apoptosis 
response-4 (Pa 4) and glyceraldehyde 3 phosphate dehydrogenase, as well as the activation 
of caspases. In cell culture and animal models therapeutic interference with the signaling 
phase of apoptosis, e.g. inhibition of the MAP kinase pathway, provides morphological and 
function protection. In contrast, inhibition of the propagation and execution phase of 
apoptosis (e.g. by inhibition of the caspases), blocks cell death but may result in survival of 
dysfunctional neuron. For full functional recovery, the combination of an antiapoptotic 
together with a neuro-restorative therapy may be necessary (Tatton et al., 2003).  
Dopaminergic cells from animal models of PD exhibit increased expression of the pro-
apoptotic protein Bax effector protease caspase-3 and caspase-8 (Tatton et al., 2003). 
Treatment with L-Dopa and dopamine agonists is associated with lower levels of anti-
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apoptotic Bcl-2 in the blood (Blandini, 2004).The peptidyl inhibitor carbobenzoxy-Val-Ala-
Asp-fluoromethylketone (zVADfmk) can protect neurons from apoptosis induced by 
mitochondrial toxins. However, its therapeutic efficacy is limited by its poor penetrability 
into the brain (Yang et al., 2004). The more potent broad-spectrum caspase inhibitor, Q-VD-
OPH, may be more promising. Specific caspase inhibitor such as acetyl-tyrosinyl-valyl-
alanyl-aspartyl-chloro-methylketone (Ac-YVAD-cmk), has also demonstrated efficacy in 
several experimental paradigms of Parkinson’s disease (Yang et al., 2004). 
Propargylamines including selegeline and rasagiline besides their MAO –B activity have 
proven to be potent anti-apoptotic agents in both in vitro and in vivo studies (Olanow, 
2006). These drugs inhibit apoptosis through caspase inhibition (Bonuccelli & Del Dotto, 
2006). Moreover, rasagiline appears to induce anti-apoptotic pro-survival proteins, Bcl-2 and 
glial cell-line derived neurotrophic factor (Maruyama, 2004). Selegiline has also been shown 
to delay the need for symptomatic therapy in untreated Parkinson’s disease patients 
(Shoulson, 1998). Further studies to determine utility of these propargylamines in the 
treatment of PD and their mechanism of neuroprotective activity are in progress.  
In an experimental study, melatonin showed neuroprotective effects against MPP+- induced 
apoptosis by inhibiting the calpain/cdk5 signaling cascade in cerebellar granule 
neurons(CGNs) (Alvira et al., 2006). Mounting evidence indicates that melatonin blocks the 
MPT dependent apoptotic fragmentation of nuclear DNA in rat astrocytes (Jou et al., 2004). 
On the other hand, human trials of melatonin showed significantly improved effect on sleep 
disturbances in PD (Medeiros et al., 2007; Dowling et al., 2005), but there were undetected 
differences in motor dysfunction (Medeiros et al., 2007). 
Oral administration of Co Q10 resulted in amelioration of mitochondria induced apoptosis 
by dose-dependent restoration of striatal complex I activity, increase in expression of Bcl-2 
as well as decrease in catalepsy score in an animal model of PD (Abdin & Hamouda, 2008). 
Treatment with CoQ10 also resulted in restoration of striatal dopamine levels (Abdin & 
Hamouda, 2008). In a multicenter clinical trial Co Q10 appears to slow progressive 
deterioration of function in PD through increased expression of Bcl-2 (Shults et al., 2002). 
However these findings were questioned in a later trial (Storch et al., 2007).  
7.3 Huntington’s disease (HD) 
Several lines of evidence point to a role for apoptosis in HD in animal models and in 
postmortem tissues. Caspase 3 has been shown to cleave mutant huntingtin and the 
activation of caspase 1 in HD brain. The expression of expanded polyglutamine residues has 
been associated with apoptotic mechanisms via caspase activation, cleavage of the death 
substrates lamin B and inhibition of caspase-activated DNAse. Bax expression in peripheral 
B and T lymphocytes and monocytes is increased in HD, and lymphoblasts derived from 
HD patients show increased stress-induced apoptotic cell death associated with caspase-3 
activation (Vis, 2005). 
Recent findings suggest a possible role for the hypoxia-inducible factor 1 (HIF-1) in HD. 
HIF-1 regulates the expression of several genes, including mediators of apoptosis, making it 
a potential target for future therapies (Correia and Moreira, 2010). Extracellular ATP 
stimulates apoptosis through stimulation of purinergic P2X7 receptors, and subsequent 
alterations in calcium permeability, both of which have been described in HD. The 
www.intechopen.com
 
Neurodegeneration 
 
174 
administration of the P2X7-antagonist Brilliant Blue-G (BBG) to HD mice prevented 
neuronal apoptosis, and attenuated motor-coordination deficits (Diaz-Hernandez et al., 
2009), suggesting the role of P2X7 in pathogenesis of HD and highlighting the therapeutic 
potential of a PsX7 antagonist for its treatment. 
Melatonin has been shown to defer the signs of HD in a 3-nitropropionic acid-induced rat 
animal model of HD (Tunez et al., 2004). In a human study administration of tryptophan, 
resulted in melatonin levels rising significantly in both of control and HD groups 
(Christofides et al., 2006). Moreover, the delayed onset of the diurnal melatonin rise in 
patients with HD has been currently reported (Aziz et al., 2009). Larger scale studies in 
detecting the level of melatonin in HD patients and further human trials on the impact of 
melatonin on HD are needed. 
7.4 Amyotrophic lateral sclerosis (ALS) 
Apoptosis is a potential mechanism of motor neuron death in ALS. Morphological studies 
are difficult as dying motor neurons may exhibit features of apoptotic as well as cytoplasmic 
and autophagic neuronal death and distinctly apoptotic cells are found only rarely in spinal 
cord specimens. Caspases, members of the cysteine protease family, are known effectors or 
executioners of apoptosis. The activity of caspase-1 (Li, et al., 2000) and caspase-9 were 
found higher in the spinal cords of patients with ALS (Inoue et al 2003). Activation of 
caspase 1 has been shown to be an early event in SOD1G37R and SOD1G85R transgenic ALS 
mice, occurring months before neuronal death, whereas activation of caspase 3 is coincident 
with the onset of motor axon loss in three different mSOD1 lines (G93A, G37R and G85R) 
(Pasinelli et al., 2000). Intraventricular injection of zVADfmk, a broad caspase inhibitor, 
suppresses caspase upregulation and delays disease onset and mortality in mouse models of 
ALS (Li et al., 2000).  
Members of the Bcl-2 family of proteins are important regulators of apoptosis, including 
both suppressors (Bcl-2, Bcl-XL) and promoters (Bax, Bad, Bak and Bcl-xS) of programmed 
cell death. Decreased expression of the anti-apoptotic proteins and increased expression of 
the proapoptotic proteins has been found in human ALS as well as transgenic mouse 
models (Guegan and Przedborski, 2003). Over-expression of Bcl-2 (Kostic et al., 1997) and 
deletion of Bax (Gould et al., 2006) independently result in delayed onset of motor decline 
and prolonged survival without reducing disease duration. 
Minocycline prolonged survival by 10-22% in transgenic mouse models of ALS (van den 
Bosch et al., 2002). In these SOD1 G37R mice, minocycline reduces the activity of caspase 1, 
caspase 3, inducible nitric oxide synthase, and p38 mitogen-activated protein kinase, and 
diminishes loss of motor neurons. Minocycline has been tested in two preliminary human 
trials and has been shown to be safe in patients with ALS (Pontieri et al., 2005). However, in 
a multicentre, phase III trial (NCT00047723) minocyline failed to show any protective effect.  
Lithium is a neuroprotective and antiapoptotic agent that promotes autophagy. It prolonged 
survival in SOD1-transgenic mice and increased the number of autophagic vacuoles in 
motor neurons (Fornai et al., 2008). Preliminary results of a small open-label study 
suggested longer survival and slower disease progression in ALS patients treated with 
lithium (Fornai et al., 2008). At least two other Phase II trials with lithium carbonate are 
under way (Clinical Trials.gov NCT00790582, NCT00925847). 
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7.5 Multiple sclerosis (MS) 
Apoptosis is important for the homeostasis of the immune system and presumably plays a 
two sided role in the pathogenesis of MS. On the other hand evidnce has been provided that 
impaired apoptosis might result in increased numbers or persistence of activated myelin –
specific T cells, thus inducing the pathophysiologic processes in MS. On the other hand, 
local tissue damage might involve apoptosis of glial and neuronal cells and lead to the 
clinical symptoms (Todaro et al., 2004). It has been hypothesized that a failure of auto-
reactive T- and B-lymphocytes, as well as activated macrophages, to undergo apoptosis 
contributes to the pathogenesis of MS (Pender and Rist, 2001). Inhibitor of apoptosis (IAP), a 
family of anti-apoptotic genes were shown to be elevated in peripheral blood immune cells 
(monocytes T cells), in MS patients (Hebb et al., 2008). Moreover antisense mediated knock 
down of inhibitor of apoptosis (IAP) family member known as X linked IAP (XIAP) reverses 
paralysis in an animal model of MS (Zehutner et al., 2007) suggesting that treatments 
targeting XIAP and perhaps other IAPs may have utility in the treatment of MS.  
Histone deacetylase 3 (HDAC 3) belongs to a family of proteins which plays an important 
role in protein acetylation, chromatin remodeling and transcription of genes, including 
those that are involved in cell proliferation and cell death. An increased expression of 
HDAC3 and relative resistance to Trichostat A (TSA) induced apoptosis in T cells in MS 
patients has been reported (Zhang et al., 2011). A number of selective and non selective 
HDAC inhibitors have been developed that could also become part of the therapeutic 
strategy in the treatment of immune disorders including MS (Zhang et al., 2011). 
8. Conclusion 
Neuroprotection in neurodegenerative diseases remains an important but elusive goal. A 
successful neuroprotective treatment could transform neurodegenerative diseases from a 
relentless progressive and disabling disease to a problem that can be managed with only a 
modest effect on quality of life. Current barriers include a lack of knowledge of the basic 
mechanism of neurodegenerative diseases and deficiencies in the methodology used to 
study disease progression. Overall, however the activity aimed at understanding and 
treating neurodegenerative diseases has grown exponentially and should ultimately result 
in better therapy for these diseases.  
The authors would like to make clear that this review cannot cover all drugs under 
investigation for the therapy of neurodegenerative diseases. For a more accurate list of these 
molecules the reader has to refer to reviews on each single neurodegenerative disorder. 
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